Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies (Q28076013)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27600150%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Frederic Castinetti

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27600150%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Maria Fleseriu

series ordinal

1

1 reference

Frederic Castinetti

series ordinal

2

1 reference

language of work or name

1 reference

December 2016

1 reference

1 December 2016

4 references

24 March 2019

2 October 2019

17 November 2019

4 September 2020

6 references

24 March 2019

2 October 2019

17 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27600150%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

4 September 2020

19

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27600150%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

643-653

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27600150%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

6

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27600150%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

31 May 2020

copyright license

4 references

24 March 2019

2 October 2019

17 November 2019

on focus list of Wikimedia project

4 September 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s11102-016-0742-1

0 references

cites work

Bilateral adrenalectomy in the 21st century: when to use it for hypercortisolism?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

The Treatment of Cushing's Disease

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Management of the clinically inapparent adrenal mass ("incidentaloma")

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Opioid contribution to decreased cortisol levels in critical care patients

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Duration of adrenal inhibition following a single dose of etomidate in critically ill patients

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Stereoisomers of ketoconazole: preparation and biological activity

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Opioid and benzodiazepine contributions to etomidate-associated adrenal insufficiency

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status

24 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Cushing's syndrome: update on signs, symptoms and biochemical screening

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Cushing's syndrome: epidemiology and developments in disease management

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Treatment of Cushing's disease: a mechanistic update

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Subclinical Cushing's syndrome: current concepts and trends

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Nonconformity in the clinical practice guidelines for subclinical Cushing's syndrome: which guidelines are trustworthy?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Medical treatment of Cushing's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Medical management of Cushing's disease: what is the future?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Treatment Options in Cushing's Disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Cushing's syndrome: all variants, detection, and treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

AME position statement on adrenal incidentaloma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Ketoconazole enantiomer for the treatment of diabetes mellitus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Inhibition of aldosterone secretion and modification of electrolyte excretion in man by a chemical inhibitor of 11 beta-hydroxylation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Medical therapy of Cushing's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

The use of ketoconazole as an inhibitor of steroid production

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Blockade of HERG and Kv1.5 by ketoconazole

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Sustained Remission of Cushing's Disease with Mitotane and Pituitary Irradiation

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5080363

Multisystem morbidity and mortality in Cushing's syndrome: a cohort study

2 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0742-1

High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0742-1

Determination of the absolute configuration and solution conformation of the antifungal agents ketoconazole, itraconazole, and miconazole with vibrational circular dichroism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0742-1

Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0742-1

Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0742-1

Management of Cushing's syndrome due to ectopic adrenocorticotropin secretion with 1,ortho-1, para'-dichloro-diphenyl-dichloro-ethane: findings in 23 patients from a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0742-1

Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0742-1

LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0742-1

Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0742-1

Mitotane has a strong and a durable inducing effect on CYP3A4 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0742-1

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0742-1

Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0742-1

A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0742-1

Increased long-term remission after adequate medical cortisol suppression therapy as presurgical treatment in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0742-1

Waiting for change: symptom resolution after adrenalectomy for Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0742-1

YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells

21 January 2018

1 reference

12 December 2020

Ketoconazole and plasma and urine steroid levels in Cushing's disease

1 reference

12 December 2020

Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome

1 reference

12 December 2020

Ketoconazole in Cushing's disease: is it worth a try?

1 reference

12 December 2020

In vivo and in vitro inhibition by ketoconazole of ACTH secretion from a human thymic carcinoid tumour

1 reference

12 December 2020

The estimation of small amounts of corticosterone in rat plasma

1 reference

12 December 2020

No Untoward Effect of Long-Term Ketoconazole Administration on Electrocardiographic QT Interval in Patients with Cushing's Disease

1 reference

12 December 2020

Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?

1 reference

12 December 2020

Lomitapide at supratherapeutic plasma levels does not prolong the Qtc interval--results from a TQT study with moxifloxacin and ketoconazole

1 reference

12 December 2020

10.1007/S11102-016-0742-1

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27600150%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27600150%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

2 references